Kymera Therapeutics: Specialist in Protein Degradation Addresses a $27 Billion Market with KT-621

Kymera Therapeutics focuses on targeted protein degradation with an emphasis on developing oral therapies for immunology and oncology. Bank of America sees peak sales potential of around $6 billion for KT-621. Topline data from the accelerated BROADEN2 phase 2b study is expected before the end of 2026. With a price-to-sales ratio of 113, high losses, and increasing research and development expenses, the growth story is very speculative.   Kymera Therapeutics (KYMR) is a clinical biopharmaceutical company focusing on so-called protein...